Clinical Trial

Secondary Prophylaxis of Clostridium Difficile Infection

Study Description

Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)

The purpose of this study is to gain further knowledge regarding the effectiveness of vancomycin prophylaxis in preventing Clostridium difficile infections in order to guide physicians' practices.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - Oral Vancomycin

Oral vancomycin 125mg twice a day prescribed for the duration of antibiotics

Placebo

Matched placebo twice a day prescribed for the duration of antibiotics

Additional Information

Official Study Title

A Randomized, Double-Blinded Placebo Controlled Study To Determine the Effectiveness of Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)

Clinical Trial ID

NCT04000555

ParticipAid ID

dG6NJb